Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 May 30:21:171-175.
doi: 10.1016/j.rmcr.2017.05.013. eCollection 2017.

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

Paul Zarogoulidis  1 , Aggeliki Rapti  2 , Chrysanthi Sardeli  3 , Panagiotis Chinelis  1 , Anastasia Athanasiadou  1 , Katerina Paraskevaidou  1 , Anastasios Kallianos  4 , Lemonia Veletza  4 , Georgia Trakada  4 , Wolfgang Hohenforst-Schmidt  5 , Haidong Huang  6
Affiliations
Case Reports

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

Paul Zarogoulidis et al. Respir Med Case Rep. .

Abstract

Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erlotinib and afatinib dosage can be modified in the case of severe adverse effects. In the case of disease relapse investigation for T790M mutation has to be made either with re-biopsy or liquid biopsy and osimertinib has to be administered when T790M is diagnosed. Based on a case series we indicate which is the best approach for T790M mutation.

Keywords: Adenocarcinoma; Erlotinib and afatinib; Gefitinb; NSCLC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pleural effusion.
Fig. 2
Fig. 2
Lung lymphagiomatosis.
Fig. 3
Fig. 3
Lung lymphagiomatosis with mediastinal lymphnode enlargement.
Fig. 4
Fig. 4
Left lung mass ct biopsy.
Fig. 5
Fig. 5
Pleural effusion during medical thoracoscopy.
Fig. 6
Fig. 6
White arrow indicates pleural effusion, while red arrow lymph node.
Fig. 7
Fig. 7
Endobronchial ultrasound performed by Dr. Paul Zarogoulidis with a Pentax EB-1970UK lymph node 11 RS biopsy.
Fig. 8
Fig. 8
Left lung mass ct biopsy.
Fig. 9
Fig. 9
Disease relapse with lymph node number 7 enlargement (red arrow).
Fig. 10
Fig. 10
Endobronchial ultrasound performed by Dr. Paul Zarogoulidis with a Pentax EB-1970UK lymph node 7 biopsy.
See this image and copyright information in PMC

References

    1. Domvri K., Zarogoulidis P., Darwiche K., Browning R.F., Li Q., Turner J.F., Kioumis I., Spyratos D., Porpodis K., Papaiwannou A., Tsiouda T., Freitag L., Zarogoulidis K. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J. Cancer. 2013;4(9):736–754. - PMC - PubMed
    1. Zarogoulidis K., Zarogoulidis P., Darwiche K., Boutsikou E., Machairiotis N., Tsakiridis K., Katsikogiannis N., Kougioumtzi I., Karapantzos I., Huang H., Spyratos D. Treatment of non-small cell lung cancer (NSCLC) J. Thorac. Dis. 2013;5(Suppl 4):S389–S396. - PMC - PubMed
    1. Domvri K., Darwiche K., Zarogoulidis P., Zarogoulidis K. Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl. Lung Cancer Res. 2013;2(4):256–258. - PMC - PubMed
    1. Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J., Chirieac L.R., D'Amico T.A., DeCamp M.M., Dilling T.J., Dobelbower M., Doebele R.C., Govindan R., Gubens M.A., Hennon M., Horn L., Komaki R., Lackner R.P., Lanuti M., Leal T.A., Leisch L.J., Lilenbaum R., Lin J., Loo B.W., Jr., Martins R., Otterson G.A., Reckamp K., Riely G.J., Schild S.E., Shapiro T.A., Stevenson J., Swanson S.J., Tauer K., Yang S.C., Gregory K., Hughes M. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. JNCCN. 2017;15(4):504–535. - PubMed
    1. Huang L., Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm. Sin. B. 2015;5(5):390–401. - PMC - PubMed

Publication types

LinkOut - more resources